Gene therapy with immunotherapy for advanced head and neck or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment that combines a virus-based gene therapy injected directly into tumors with an immunotherapy drug. It aims to help people with advanced head and neck or esophageal cancer who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (and under 71 for head and neck cancer, under 76 for esophageal cancer).
- You have advanced head and neck cancer or esophageal squamous cell carcinoma that has come back or spread.
- You have had at least one prior treatment (platinum-based chemo for head and neck, or immunotherapy for esophageal).
- You have a tumor that can be injected (at least 2 cm for head and neck, or a superficial lymph node for esophageal).
- You are generally well enough to carry out daily activities (ECOG 0-2 for head and neck, 0-1 for esophageal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can improve outcomes for patients with a certain type of stomach or esophageal cancer that can be surgically removed. It aims to see if this approach shrinks tumors and helps prevent recurrence.
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.